- Lobbying
- Lobbying by Allied BioScience, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
David Stratton Edwards | Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015 Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015 |
Jack Victory | Senior Advisor, House Majority Leader Tom DeLay- 1/02 - 05. Policy Advisor, House Majority Whip Tom DeLay - 5/ 01-1/02. LD for Rep. Jim Gibbons - 6/98 - 5/01. Senior LA, Systems Administrator, Rep. Jim Gibbons from 6/98 - 5/01. |
William Steve Southerland | William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015. |
Tom Wharton | Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012 Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011 |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Health & Human Services - Dept of (HHS)
Food & Drug Administration (FDA)
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Environmental Protection Agency (EPA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Centers For Disease Control & Prevention (CDC)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Registration
Issue(s) they said they’d lobby about: Regulatory approval for antimicrobial product. Introduction with researchers and practitioners at NIH and CDC concerning efficacy of technology..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate